Replimune down as FDA’s top cancer drug regulator reportedly intervened in drug rejection

20 hours ago 1

• Healthcare
• On the Move

JHVEPhoto

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset, RP1, causing the treatment’s eventual rejection.

In late

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Replimune down as FDA’s top cancer drug regulator reportedly intervened in drug rejection